Impact of molecular profiling on clinical trial design for glioblastoma

被引：6

作者：

Chakravarti A. ^{[1
]}

Tyndall E. ^{[1
]}

Palanichamy K. ^{[1
]}

Mehta M. ^{[1
]}

Aldape K. ^{[1
]}

Loeffler J. ^{[1
]}

机构：

[1] Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114

来源：

Current Oncology Reports | 2007年 / 9卷 / 1期

关键词：

Temozolomide; CCNU; Icatin;

D O I：

10.1007/BF02951429

中图分类号：

学科分类号：

摘要：

This review highlights the ways in which molecular and genetic profiling of malignant gliomas has led to intelligent clinical trial: design. The review also highlights known resistance mechanisms to conventional therapies in malignant gliomas and potential strategies to overcome these mechanisms with the use of targeted therapy. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：71 / 79

页数：8

共 45 条

[1]

Newlands E.S., Stevens M.F., Wedge S.R., Et al., Temozolomide: A review of its discovery, chemical properties, pre-clinical development, and clinical trials, Cancer Treat Rev, 23, pp. 35-61, (1997)

[2]

Wedge S.R., Porteous J.K., Glaser M.G., Et al., In vitro evaluation of temozolomide combined with X-irradiation, Anticancer Drugs, 8, pp. 92-97, (1997)

[3]

Newlands E.S., Blackledge G., Slack R.S., Phase I trial of temozolomide (CCRG 81045: M&B 39831:NSC 362856), Br J Cancer, 65, pp. 287-291, (1992)

[4]

Yung W.K., Albright R.E., Olson J., Et al., A phase II study of temozolomide vs. procarbazine in patients with glioblastoma at first relapse, Br J Cancer, 83, pp. 588-593, (2000)

[5]

Stupp R., Dietrich P.Y., Ostermann Kralievic S., Et al., Promising survival for patients with newly-diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide, J Clin Oncol, 20, pp. 1375-1382, (2002)

[6]

Stupp R., Mason W.P., van den Bent M.J., Et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, pp. 987-996, (2005)

[7]

Hegi M.E., Diserens A.C., Gorlia T., Et al., MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, pp. 997-1003, (2005)

[8]

Hackel P.O., Zwick E., Prenzel N., Ullrich A., Et al., Epidermal growth factor receptors: Critical mediators of multiple receptor pathways, Curr Opin Cell Biol, 11, pp. 184-189, (1999)

[9]

Woodburn J.R., The epidermal growth factor receptor and its inhibition in cancer therapy, Pharmacol Ther, 82, pp. 241-250, (1999)

[10]

Zwick E., Prenzel N., Ullrich A., Et al., The EGF receptor as central transducer of heterologous signalling systems, Trends Pharmacol Sci, 20, pp. 408-412, (1999)

← 1 2 3 4 5 →